WEST PHARMACEUTICAL SERVICES INC WST revenue by segment, product and geography
In its fiscal year ending 2025-12-31, WEST PHARMACEUTICAL SERVICES INC reported revenue across 2 business segments; the largest, Proprietary Products, was $2.49B, 81.1% of the filed sum (+6.8% against the prior period in the same filing).
Reported segment mix
figures as filed · share of the filed sum · change vs the prior period in the same filing- Proprietary Products$2.49B81.1%+6.8% yoy
- Contract Manufactured Products$582M18.9%+4.2% yoy
Members sum to the consolidated $3.07B for this period.
- United States$1.33B43.3%+8.0% yoy
- Other Europe Countries$451M14.7%+17.0% yoy
- Germany$380M12.4%+2.1% yoy
- Other countries$353M11.5%+4.2% yoy
- Ireland$333M10.8%+3.1% yoy
- France$227M7.4%-6.4% yoy
Members sum to the consolidated $3.07B for this period.
- Proprietary Products$723M82.8%no prior
- West Vantage Segment$150M17.2%no prior
Change is against the same quarter a year earlier, as reported in the same 10-Q.
Source: SEC DERA Financial Statement and Notes data sets. Dimensional XBRL facts on the business-segment, product/service and geographic axes; the engine keeps the accession of every figure. Descriptive and educational, not advice.
About these figures
Companies tag segment, product and geographic revenue as dimensional XBRL facts in their 10-K and 10-Q filings. The SEC publishes those facts in its DERA Financial Statement and Notes data sets; TrendNalysis ingests each monthly file and serves the facts exactly as filed, keyed to the accession of the filing. Shares are of the filed sum. Where a filer tags more than one breakdown on one axis, the sum exceeds consolidated revenue and no shares are computed; where the members do not add up to the consolidated figure, the residual is stated rather than hidden. Missing is never zero.
Descriptive and educational; not investment advice. Methodology and data lineage.